Overview
Selank Overview
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is built on tuftsin, a naturally occurring four-residue peptide (Thr-Lys-Pro-Arg), with a Pro-Gly-Pro motif added at the C-terminus. Selank was first developed at the Institute of Molecular Genetics of the Russian Academy of Sciences.
The Pro-Gly-Pro extension is reported to make Selank more resistant to enzymatic breakdown than tuftsin, which makes it a useful model for studying peptide stability and signaling. In preclinical laboratory models, Selank is studied for its interactions with GABAergic signaling, monoamine neurotransmitter levels, enkephalin-degrading enzyme activity, and BDNF expression in hippocampal and prefrontal tissue. In vitro work also examines its effect on cytokine and chemokine gene expression, including IL-6, in cultured cell systems.
Each lot is made by solid-phase peptide synthesis, third-party tested, and supplied with a Certificate of Analysis.
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP) |
|---|---|
| Sequence length | 7 amino acids |
| Also known as | TP-7, Selanc, tuftsin analog |
| Molecular formula | C33H57N11O9 |
| Molecular weight | 751.9 g/mol |
| CAS number | 129954-34-3 |
| PubChem CID | 11765600 |
| Form | Lyophilized powder |
| Purity | >99% by HPLC, per COA |
| Storage | -20°C, sealed and protected from light |
Certificate of Analysis
| Date | Lot | Certificate |
|---|---|---|
| Selank - 10mgNov 3, 2026 | 26082802 | View COA |